Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:NTLA NASDAQ:REPL NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.43+2.1%$2.17$1.43▼$3.98$244.00M1.61127,784 shs172,212 shsNTLAIntellia Therapeutics$11.42$11.62$5.90▼$23.76$1.23B2.283.83 million shs3.33 million shsREPLReplimune Group$5.73-4.7%$6.68$2.68▼$17.00$447.28M0.512.07 million shs1.38 million shsXNCRXencor$8.60+1.2%$8.32$6.92▼$27.24$613.35M0.82711,026 shs791,753 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.58%+14.08%+25.26%-23.58%NTLAIntellia Therapeutics0.00%-5.31%+3.91%+27.46%-48.26%REPLReplimune Group0.00%-9.48%+3.06%-41.71%-48.52%XNCRXencor0.00%+0.58%+11.98%-4.97%-59.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.43+2.1%$2.17$1.43▼$3.98$244.00M1.61127,784 shs172,212 shsNTLAIntellia Therapeutics$11.42$11.62$5.90▼$23.76$1.23B2.283.83 million shs3.33 million shsREPLReplimune Group$5.73-4.7%$6.68$2.68▼$17.00$447.28M0.512.07 million shs1.38 million shsXNCRXencor$8.60+1.2%$8.32$6.92▼$27.24$613.35M0.82711,026 shs791,753 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.58%+14.08%+25.26%-23.58%NTLAIntellia Therapeutics0.00%-5.31%+3.91%+27.46%-48.26%REPLReplimune Group0.00%-9.48%+3.06%-41.71%-48.52%XNCRXencor0.00%+0.58%+11.98%-4.97%-59.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.67Moderate Buy$10.00311.52% UpsideNTLAIntellia Therapeutics 2.56Moderate Buy$27.11137.40% UpsideREPLReplimune Group 2.10Hold$6.5013.44% UpsideXNCRXencor 2.67Moderate Buy$22.25158.72% UpsideCurrent Analyst Ratings BreakdownLatest ACIU, REPL, XNCR, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ACIUAC ImmuneZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/8/2025ACIUAC ImmuneBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/3/2025XNCRXencorBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$23.00 ➝ $12.009/2/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.008/21/2025XNCRXencorRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $15.008/13/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/11/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $60.008/8/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$50.00 ➝ $45.008/8/2025NTLAIntellia TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $21.008/8/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M7.87N/AN/A$1.29 per share1.88NTLAIntellia Therapeutics$57.88M21.18N/AN/A$8.56 per share1.33REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/AXNCRXencor$110.49M5.55N/AN/A$9.63 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest ACIU, REPL, XNCR, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/A8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33NTLAIntellia TherapeuticsN/A5.195.19REPLReplimune Group0.216.946.94XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%NTLAIntellia Therapeutics88.77%REPLReplimune Group92.53%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%NTLAIntellia Therapeutics3.10%REPLReplimune Group5.20%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableNTLAIntellia Therapeutics600107.35 million104.02 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableXNCRXencor28071.32 million67.59 millionOptionableACIU, REPL, XNCR, and NTLA HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Buys 384,509 Shares of Xencor, Inc. $XNCRSeptember 10, 2025 | marketbeat.com155,580 Shares in Xencor, Inc. $XNCR Bought by Cubist Systematic Strategies LLCSeptember 9, 2025 | marketbeat.comTrexquant Investment LP Acquires 50,119 Shares of Xencor, Inc. $XNCRSeptember 8, 2025 | marketbeat.comRBC Cuts Xencor (XNCR) Price Target but Keeps Outperform RatingSeptember 8, 2025 | msn.comXencor (NASDAQ:XNCR) Cut to Neutral at Bank of AmericaSeptember 6, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Gap Down Following Analyst DowngradeSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Cut to "Neutral" at Bank of AmericaSeptember 5, 2025 | marketbeat.comBVF Inc. IL Buys 451,381 Shares of Xencor, Inc. $XNCRSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Gap Down After Analyst DowngradeSeptember 5, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Trading Up 6% - What's Next?September 4, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Holdings in Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comB of A Securities Downgrades Xencor (XNCR)September 4, 2025 | msn.comPanagora Asset Management Inc. Acquires 260,124 Shares of Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | americanbankingnews.comXencor downgraded to Neutral from Buy at BofASeptember 3, 2025 | msn.comBeyond The Numbers: 4 Analysts Discuss Xencor StockSeptember 3, 2025 | benzinga.comXencor downgraded to Neutral at BofA on long development timelinesSeptember 3, 2025 | msn.comBraidwell LP Boosts Stock Position in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNantahala Capital Management LLC Purchases New Shares in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Purchases 34,765 Shares of Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025ACIU, REPL, XNCR, and NTLA Company DescriptionsAC Immune NASDAQ:ACIU$2.43 +0.05 (+2.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 05:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Intellia Therapeutics NASDAQ:NTLA$11.42 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.86 +0.44 (+3.81%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Replimune Group NASDAQ:REPL$5.73 -0.28 (-4.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.72 -0.02 (-0.26%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Xencor NASDAQ:XNCR$8.60 +0.10 (+1.18%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.62 +0.02 (+0.24%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
